News

Nova Mentis Announces Change of Directors and Officers

Vancouver, British Columbia – January 03, 2023 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”) announces the appointment of Dr. Georg Hochwimmer to the Company’s Board of Directors, effective December 29, 2023.  Dr. Hochwimmer is Chief Analyst at General Research, GmbH, a leading Munich-based securities research and analysis
Read More »

Nova Mentis Applauds Government Decision to Create Rare Disease Advisory Group

Vancouver, British Columbia – November 03, 2023 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased the Canadian government has established a new Implementation Advisory Group (IAG) for drugs for rare diseases, as part of its National Strategy to help
Read More »

Participant Screening Underway in Canada’s First Psilocybin Clinical Trial for Fragile X Syndrome

Vancouver, British Columbia – August 30, 2023 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased to provide an update on its Phase IIA clinical trial testing psilocybin for the treatment of fragile X syndrome (FXS),
Read More »

Nova Mentis to Enter mRNA AI Diagnostics Business

Vancouver, British Columbia – April 26, 2023 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased to announce the launch of SwabAi Diagnostics Inc. (SwabAi). On June 16, 2022, NOVA filed a patent titled “Diagnosing, Monitoring and
Read More »

Nova Mentis Begins Recruitment in First-of-its-Kind Health Canada Psilocybin Trial

Vancouver, British Columbia – April 18, 2023 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased to announce that it has begun recruiting participants into the first-ever clinical trial investigating the effects of psilocybin on the
Read More »

Nova Mentis Receives Institutional Review Board Approval to Commence Psilocybin Clinical Trial

Vancouver, British Columbia – April 11, 2023 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased to announce it has received institutional review board (IRB) approval in Canada to begin its human study testing the efficacy
Read More »